Overview

TMC125-C223: TMC125 in HIV-1 Infected Subjects

Status:
Completed

Trial end date:
2005-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate the ability of TMC125, a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), to lower the amount of virus in your blood when administered twice daily for 48 weeks.

Phase:

Phase 2

Details

Lead Sponsor:

Tibotec Pharmaceuticals, Ireland

Treatments:

Etravirine